ClinicalTrials.gg
RecruitingNCT05490433ROMUpdated Nov 17, 2025

Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction

An interventional study of Robot-assisted Nipple-Sparing Mastectomy (RNSM) and Conventional nipple sparing mastectomy(CNSM) in Breast Cancer Classified as TNM Stage 0-IIIa, sponsored by Yonsei University. Recruiting at 17 sites in South Korea. Open to female participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Yonsei University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
790
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Breast Neoplasms by Yonsei University — 4 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · Yonsei University.

Planned enrollment
2nd of 23
790 · median 84
Started
2022
with 3 others
No phase
11 of 28
2 open now
Registered
23rd of 28
by date

Among the 28 studies in Breast Neoplasms by Yonsei University, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 with no phase, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 28 studies in Breast Neoplasms by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Yonsei University, or all of them as a file.
02

Study summary

Research Purpose The present study is designed to generate the strongest evidence available on the role of robotic surgical systems in breast cancer surgery and to elucidate the clinical value of immediate breast reconstruction (IBR) conducted in conjunction with robot-assisted nipple-sparing mastectomy (RNSM).

Study Design Overview This study is a prospective, multicenter, randomized clinical trial (ROM Trial) designed to compare the oncologic outcomes of robot-assisted nipple-sparing mastectomy (RNSM) with conventional nipple-sparing mastectomy (CNSM), which includes both traditional and open-chest approaches. Previous retrospective studies of robot-assisted endoscopic surgery have suggested a short learning curve, demonstrating technical feasibility and reproducibility even for less experienced surgeons. However, the absence of rigorously designed randomized clinical trials remains a major global barrier to the broader adoption of robotic breast surgery.

In the ROM Trial, eligible patients who provide written informed consent will be randomly assigned in a 1:1 ratio to undergo either RNSM or CNSM. Participants will be blinded to group allocation until the day of surgery (single-blind design). Immediate breast reconstruction (IBR) will be performed in all patients, with the reconstruction method determined in consultation with the breast and/or plastic surgeon following mastectomy.

Read the detailed description

Background Robot-assisted nipple-sparing mastectomy (RNSM) has emerged as an approach for both breast cancer treatment and risk-reducing mastectomy in women carrying high-risk pathogenic variants. Although several studies have reported that RNSM is a feasible procedure, concerns remain that it is performed only by a small number of specialized surgeons, and data on oncologic outcomes and patient-reported outcomes (PROs) remain limited. Recently, the United States Food and Drug Administration and several expert surgeons have cautioned that robotic breast surgery should be performed only by highly trained specialists, and that the benefits, risks, and alternative treatment options must be thoroughly discussed with patients to ensure fully informed decision-making.

To promote the safe and standardized application of RNSM, the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) was established with the mission to evaluate, standardize, and disseminate this advanced surgical technique.

Study Design We designed a prospective, multicenter, randomized clinical trial (Robot vs. Open Nipple-sparing Mastectomy Trial; ROM Trial) to evaluate the oncologic outcomes of RNSM with immediate breast reconstruction (IBR), compared with conventional open nipple-sparing mastectomy (CNSM) with IBR.

Previous retrospective studies on robot-assisted endoscopic breast surgery have demonstrated a short learning curve, suggesting that the technique is feasible and reproducible even for less experienced surgeons. However, the absence of rigorously designed randomized controlled trials has been a major limitation in expanding the global adoption of robotic breast surgery. The ROM Trial was therefore established to address this unmet need.

Data Collection Clinical and pathological data to be collected include: height, weight, breast volume/weight, age, germline likely pathogenic/pathogenic mutation status, affected breast, bilaterality, breast ptosis, tumor size, TNM stage, histologic grade, histologic type, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67 index, nipple involvement, neoadjuvant/adjuvant treatment status, postoperative complications (Clavien-Dindo classification), operative time, margin involvement, postoperative drainage amount/duration, risk-reducing mastectomy (RRM) status, reconstruction type, recurrence status, healthcare cost data, and follow-up information.

Patient Satisfaction Assessment Between 3 and 12 months (±30 days) after the final surgery, patients will be surveyed using the validated Korean version of the BREAST-Q questionnaire to evaluate satisfaction with surgery.

Cost-Effectiveness Assessment (Optional) Cost-effectiveness according to surgical method will be evaluated between 3 and 12 months (±30 days) after the final surgery, using the Korean version of the EuroQol 5-Dimension (EQ-5D) questionnaire.

03

Conditions studied

  • Breast Cancer Classified as TNM Stage 0-IIIa

Browse trials for

Keywords

  • Breast cancer
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women (≥19 years) scheduled to undergo therapeutic mastectomy for breast cancer who desire immediate breast reconstruction (IBR).
  • Breast cancer classified as clinical TNM stage 0 to IIIA, based on preoperative evaluation according to the 8th edition of the AJCC anatomic staging system.
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Patients scheduled for breast-conserving surgery or deemed ineligible for immediate breast reconstruction (IBR).
  • Clinical evidence of nipple or skin involvement on preoperative evaluation.

    • Pregnant or breastfeeding women.
    • Tumors consisting exclusively of lobular carcinoma in situ (LCIS).
    • Paget's disease of the breast.
    • Inflammatory breast cancer.
    • Male breast cancer.
    • Clinical stage IIIB-IV disease on preoperative evaluation.
    • breast size equal to or larger than cup E
    • History of breast cancer or bilateral breast cancer (including metachronous or synchronous disease).
    • History of non-breast , with the exception of non-melanoma skin cancer or papillary/follicular thyroid carcinoma.
    • Special histologic subtypes of breast tumors (e.g., phyllodes tumor, sarcoma, lymphoma).
    • Age >70 years.
    • (ASA) physical status classification grade ≥4.
    • Inability to provide .
    • History of prior chest radiotherapy.
    • Patients who have not undergone preoperative testing for virus (HBV), virus (HCV), and (HIV), which is required for liability insurance coverage.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
790 participants (estimated)

Study arms

  • Experimental
    robot assisted nipple sparing mastectomy(RNSM)

    Robotic nipple sparing mastectomy, robotic mastectomy, hybrid robotic nipple sparing mastectomy, robotic nipple mammary complex and skin sparing mastectomy, robot nipple sparing mastectomy

    Procedure: Robot-assisted Nipple-Sparing Mastectomy (RNSM)

  • Active comparator
    Conventional nipple sparing mastectomy(CNSM)

    Total mastectomy, mastectomy, nipple sparing mastectomy, skin sparing mastectomy, nipple sparing breast resection, open nipple sparing mastectomy, general nipple sparing Mammastectomy, an open-window nipple sparing mastectomy

    Procedure: Conventional nipple sparing mastectomy(CNSM)

Interventions

  • ProcedureRobot-assisted Nipple-Sparing Mastectomy (RNSM)

    Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision. During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered.

  • ProcedureConventional nipple sparing mastectomy(CNSM)

    Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted. During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered.

06

What researchers measure

Primary outcomes

  1. 5-year disease-free survival rate(DFS)

    From the date of surgery to the first qualifying event, or censored at the date of last follow-up if no event occurs * Events: local/regional/distant recurrence, contralateral breast cancer, or all-cause mortality. * Local recurrence: recurrence in the ipsilateral breast or chest muscles, ipsilateral chest wall, or nipple-areola complex (NAC). * Regional recurrence: recurrence in the ipsilateral axillary lymph nodes, ipsilateral infra/supraclavicular lymph nodes, or ipsilateral internal mammary lymph nodes. * intraepithelial carcinoma is included as an event for local recurrence and contralateral breast cancer. * patients without an event are censored at the last known disease assessment. Statistical analysis (non-inferiority) * DFS will be analyzed using a Cox proportional hazards model stratified by institution and clinical stage. * The hazard ratio (HR) for RNSM vs CNSM and its 95% confidence interval (CI) will be estimated.

    Time frame: The DFS period is calculated from the date of surgery to the time of the first event, or censored at the date of last follow-up if no event is reported.

Secondary outcomes

  1. 5-Year Overall Survival (OS)

    Events for OS are defined as death from any cause. OS time will be calculated in months from the date of surgery to the date of the event.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  2. 5-Year Breast Cancer-Specific Survival (BCSS)

    Events for BCSS include death attributable to breast cancer. Deaths from unrelated causes will be censored.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  3. 5-Year Distant Recurrence-Free Survival (DRFS)

    Events for DRFS are defined as the first occurrence of distant recurrence. Local recurrence and contralateral breast cancer will be censored.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  4. 5-Year Locoregional Recurrence-Free Survival (LRFS)

    Events for LRFS include the first occurrence of local or regional recurrence. Distant recurrence and contralateral breast cancer will be censored.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  5. 5-Year Nipple Recurrence Rate (NR)

    NR is defined as the first recurrence of the nipple-areola complex (NAC). Recurrence in the ipsilateral breast or chest muscles, chest wall, regional lymph nodes, contralateral breast, or distant sites will be censored.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  6. Positive Margin Rate (at Surgery)

    A positive margin is defined as tumor involvement of the NAC, superficial, posterior, or circumferential margins confirmed in the final pathology report. The overall positive margin rate will be analyzed.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  7. Conversion Rate to Open Surgery (RNSM Group Only; at Surgery)

    In the RNSM group, intraoperative conversion from RNSM to CNSM will be analyzed. Reasons for conversion will be documented.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  8. Operation time

    Total operative time includes both mastectomy and reconstruction. Each component will be measured separately and analyzed.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  9. 30-Day Postoperative Complication Rate

    The complication rate within 30 days post-surgery will be calculated as the total number of complications per patient in each group. Both the total number of complications per patient and the number of Clavien-Dindo grade III or higher complications per patient will be analyzed. NAC necrosis rate will also be evaluated.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  10. Clavien-Dindo Classification of Postoperative Complications (within 180 days)

    Postoperative complications will be assessed using the Clavien-Dindo classification. Grade III or higher complications, including flap or implant loss, will be analyzed.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  11. Flap or Implant Loss Rate (within 1 year postoperatively)

    Time frame: Flap or implant loss within 1 year of surgery will be recorded and analyzed.

  12. Patient-Reported Outcomes (between 3 and 12 months postoperatively)

    Breast satisfaction will be evaluated using the BREAST-Q version 2.0 scale administered before and after mastectomy. Higher scores indicate better outcomes.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  13. Surgeon Satisfaction (between 3 and 12 months postoperatively)

    Surgical satisfaction will be evaluated by the operating surgeon. Overall symmetry, postoperative scarring, and NAC symmetry will be scored using a 0-10 scale, with higher scores indicating better outcomes. Overall symmetry, postoperative scar, and NAC symmetry are measured using scoring system 0-10. The higher scores are, the better an outcome is.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  14. Cost-Effectiveness (between 3 and 12 months postoperatively; optional)

    Cost-effectiveness will be assessed between 3 and 12 months after the final surgery using the Korean version of the EuroQol 5-Dimension (EQ-5D) questionnaire. Higher scores indicate better outcomes across all dimensions.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

  15. 30-Day Estimated Postoperative Complication Rate

    Based on a sample size of 790 (632 after accounting for 20% dropout), the study has at least 80% power to detect various assumed complication rates between the conventional and robotic groups, with a non-inferiority margin of 7.5%. The assumed 30-day complication rate for the conventional group is 25-50%. The maximum 30-day complication rate for the robotic group to be considered non-inferior is presented in Table 2. These will be analyzed as secondary endpoints.

    Time frame: secondary outcome is calculated from the date of surgery to the time the first event occurs, or if the event is not reported on the last follow-up date.(After 5 years of follow-up observation of subject registration)

07

Study locations

11 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jun 2032, 116 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 116 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 5, 2022
StartActual
Oct 26, 2022
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05490433
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Oct 26, 2022
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Nov 17, 2025

Study contacts

Hyung Seok Park, MD, PhD
Contact
imgenius@yuhs.ac
82-10-6760-2974
Hyung Seok Park, MD, PhD
principal investigator · Yonsei University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion